T3	Effect 24 58	focal segmental glomerulosclerosis
T5	Subject 103 119	two cases of CML
T6	Treatment 133 141	IFNalpha
T7	Population 103 106	two
T8	Sub-Disorder 116 119	CML
T9	Drug 133 141	IFNalpha
